PAT

Global Photoacoustic Imaging (Tomography, Microscopy) Market Size, Share & Trends Analysis Report 2023-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, December 12, 2023
Radiology, Health Technology, Health, Research, Conditional sentence, Prevalence, Photoacoustic imaging, Sound, Application, PAT, Patient, USD, Light, PAM, Photoacoustic microscopy, Diagnosis, Growth, PAI, Medical imaging

The "Photoacoustic Imaging Market Size, Share & Trends Analysis Report By Product (Photoacoustic Tomography (PAT), Photoacoustic Microscopy (PAM)), By Type (Pre-clinical, Clinical), By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Photoacoustic Imaging Market Size, Share & Trends Analysis Report By Product (Photoacoustic Tomography (PAT), Photoacoustic Microscopy (PAM)), By Type (Pre-clinical, Clinical), By Application, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global photoacoustic imaging market size is anticipated to reach USD 339.02 million by 2030.
  • The advancement in photoacoustic imaging (PAI) offers a unique combination of structural and functional information, making it valuable for early disease detection and monitoring in healthcare.
  • In the near future, it is also anticipated that manufacturers will increase their promotional efforts for photoacoustic imaging systems, which will accelerate their utilization.

ATMA and Cena Life Launch Nationwide Psychedelic-Assisted Therapy Healthcare Network

Retrieved on: 
Thursday, December 7, 2023
Psilocybin, KAP, Depression, Safety, Nursing, SAP, Transcranial magnetic stimulation, Physician, MDMA, Surgeon, Kat, AB, Patient, Ecosystem, Registered nurse, City, ATMA, Special access program, Anxiety, PTSD, Psychedelic drug, Therapy, PAT

CALGARY, AB, Dec. 7, 2023 /PRNewswire/ - ATMA Journey Centers Inc. ("ATMA") and Cena Life , forefront leaders in advancing psychedelic-assisted therapy (PaT) are  pleased to announce the opening of a  licensed Calgary Clinic and the establishment of the Psychedelic-Assisted Therapy Healthcare Network, a national clinical network for the emerging psychedelic-assisted therapy sector.

Key Points: 
  • CALGARY, AB, Dec. 7, 2023 /PRNewswire/ - ATMA Journey Centers Inc. ("ATMA") and Cena Life , forefront leaders in advancing psychedelic-assisted therapy (PaT) are  pleased to announce the opening of a  licensed Calgary Clinic and the establishment of the Psychedelic-Assisted Therapy Healthcare Network, a national clinical network for the emerging psychedelic-assisted therapy sector.
  • Like the evolving services in the Cena Life practice in Edmonton, the Calgary clinic will offer KaT, rTMS, SAP application support as well as regular psychological counselling services.
  • Together, we aim to create a network that prioritizes patient well-being while fostering a collaborative and supportive environment for practitioners.
  • Practitioners wishing to join The Psychedelic Healthcare Network are encouraged to take the required training for PaT in advance of practice.

Numinus Wellness Inc. Announces Fourth Quarter and Full Year Fiscal 2023 Results

Retrieved on: 
Wednesday, November 29, 2023
Psilocybin, EBITDA, Health Canada, Research, CCR, Ageing, MDMA, Learning management system, Clinical trial, PAT, MAPS, FDA, Trial of the century, Partnership, Conditional sentence, Growth, TSX, Payment card, Health care, Nursing, Pharmaceutical industry, Beauty salon, Phoenix

VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months and fiscal year ended August 31, 2023 ("Q4 2023").

Key Points: 
  • VANCOUVER, BC, Nov. 29, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months and fiscal year ended August 31, 2023 ("Q4 2023").
  • For the fiscal year ending August 31, 2023, revenue increased by 256.9% over the previous fiscal year.
  • On an annual basis, the gross margin was 36.1% in fiscal year 2023, compared to 27.4% in fiscal year 2022.
  • Numinus Bioscience will remain a legal entity under Numinus Wellness Inc., ensuring the Company will retain all intellectual property, patents, and regulatory licenses.

A Global Leader in Animal Health Selects ValGenesis VLMS to Digitize its Corporate Validation Process

Retrieved on: 
Tuesday, November 21, 2023
Animal, Biotechnology, PAT, Technology transfer

SANTA CLARA, Calif., Nov. 21, 2023 /PRNewswire/ -- ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a global leader in animal health selected ValGenesis VLMS to digitize its corporate validation process.

Key Points: 
  • SANTA CLARA, Calif., Nov. 21, 2023 /PRNewswire/ -- ValGenesis, Inc., the market leader in enterprise validation lifecycle management systems (VLMS), today announced that a global leader in animal health selected ValGenesis VLMS to digitize its corporate validation process.
  • The company has pharmaceutical, biotechnology, and animal health businesses in more than 150 countries and is working on premium innovations to predict, prevent, and treat diseases in animals.
  • ValGenesis will provide technology transfer services and streamline multiple processes at the company's manufacturing site in Brazil that produces a high-volume commercial product.
  • "We see significant opportunities to modernize processes in the animal health sector with our industry standard digital validation platform which enables transparent processes that are standardized, optimized, and audit-ready."

Aprecia and Battelle Are Impacting The Pharmaceutical Industry Through 3D Printing Innovation

Retrieved on: 
Wednesday, November 15, 2023
Pharmacist, 3D, Tablet, PAT, Research, Patient, Senior, Partnership, 3D printing

The advantage of 3D printing technology has revolutionized various industries, and now 3D printing is poised to disrupt the pharmaceutical manufacturing sector.

Key Points: 
  • The advantage of 3D printing technology has revolutionized various industries, and now 3D printing is poised to disrupt the pharmaceutical manufacturing sector.
  • Aprecia Pharmaceuticals' 3D printing platforms overcome these challenges by enabling the creation of highly customizable, patient-specific medicines.
  • The key benefit of Aprecia's 3D printing platform is its capacity to produce a variety of functionally differentiated drug products previously unachievable with traditional manufacturing.
  • The development partnership began in July 2021, when Aprecia engaged Battelle to conduct a feasibility assessment of 3D printed, customized tablets that contained multiple active pharmaceutical ingredients.

Hardman & Co Research on Surface Transforms (SCE): Funding for growth: Open Offer

Retrieved on: 
Sunday, December 10, 2023
SCE, PAT, Growth, OEM

Hardman & Co Research on Surface Transforms (SCE): Funding for growth: Open Offer

Key Points: 
  • Hardman & Co Research on Surface Transforms (SCE): Funding for growth: Open Offer
    The issuer is solely responsible for the content of this announcement.
  • In the past two years, Surface Transforms (SCE) has quadrupled its order book, raised monthly sales run rates from £0.2m to £1.0m and expanded its capacity four-fold to a £20m pa sales rate.
  • A 3 November update pointed to production teething troubles.
  • October sales of £1.0m were below prior estimates, so we significantly reduced our 2023 and 2024 estimates.

Redington announces Q2FY24 results: Reports notable QoQ growth

Retrieved on: 
Tuesday, November 7, 2023
Cloud, Yoy, Luigi, Bank statement, Quarter, EBIT, PAT, NSE, Growth, Compact Disc manufacturing

22,297 Crore revenue for Q2FY24, 5% QoQ

Key Points: 
  • 22,297 Crore revenue for Q2FY24, 5% QoQ
    EBIT and PAT grew by 17% and 22% respectively, QoQ
    CHENNAI, India, Nov. 7, 2023 /PRNewswire/ -- Redington Ltd (NSE: REDINGTON), today announced its financial results for Q2 FY24, which ended on September 30, 2023.
  • It successfully navigated through market uncertainties driven by worldwide economic and geo-political issues to deliver strong growth across all geographies – India, Middle East Africa region and Turkey.
  • 22,297 Crore, overall global revenues for Q2FY24 have grown by a strong 17% YoY and 5% QoQ.
  • *The detailed Financial Report for Q2FY24 can be accessed here: Financial Reports – Redington (redingtongroup.com)
    Certain statements in this release are forward-looking statements.

Redington announces Q2FY24 results: Reports notable QoQ growth

Retrieved on: 
Tuesday, November 7, 2023
Cloud, Yoy, Luigi, Bank statement, Quarter, EBIT, PAT, NSE, Growth, Compact Disc manufacturing

22,297 Crore revenue for Q2FY24, 5% QoQ

Key Points: 
  • 22,297 Crore revenue for Q2FY24, 5% QoQ
    EBIT and PAT grew by 17% and 22% respectively, QoQ
    CHENNAI, India, Nov. 7, 2023 /PRNewswire/ -- Redington Ltd (NSE: REDINGTON), today announced its financial results for Q2 FY24, which ended on September 30, 2023.
  • It successfully navigated through market uncertainties driven by worldwide economic and geo-political issues to deliver strong growth across all geographies – India, Middle East Africa region and Turkey.
  • 22,297 Crore, overall global revenues for Q2FY24 have grown by a strong 17% YoY and 5% QoQ.
  • *The detailed Financial Report for Q2FY24 can be accessed here: Financial Reports – Redington (redingtongroup.com)
    Certain statements in this release are forward-looking statements.

Osmolality Analysis in Bioprocessing: From Theory to Practice, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Monday, November 6, 2023
Molality, Osmotic pressure, Glycoprotein, Cell, Horizon Fuel Cell Technologies, PAT, Glycosylation, Growth, A-DNA, QC, Immunoglobulin G, Buffer, CHO, Fine chemical, Medical imaging

TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production. Osmolality is described as the measurement of the contribution of all the dissolved solutes to the osmotic pressure of a solution. In biopharma, osmolality is usually used as a critical quality control (QC) check for cell culture media, buffers and formulated drug products. It is also used as a critical process parameter during upstream cell culture and downstream filtration.

Key Points: 
  • Attendees will learn about using osmolality analysis in Chinese hamster ovary (CHO) cell health studies.
  • The featured speakers will discuss current uses and future potential for osmolality analysis at the upstream and downstream stages of bioprocessing.
  • TORONTO, Nov. 6, 2023 /PRNewswire-PRWeb/ -- Discover an informative webinar exploring the impact of osmolality in bioprocessing and in correlation with immunoglobulin G (IgG) production.
  • Join this webinar to gain insights into osmolality in correlation with IgG production in a media development project.

NYU Langone Receives $9.8 Million to Advance Pediatric Medicine

Retrieved on: 
Monday, October 30, 2023
Science, Hassenfeld Children's Hospital, Longevity, Physician, NYU Langone Health, Research, NYU, Michael M. Gottesman, New York University Grossman School of Medicine, PAT, Patient, Diagnosis, Hospital, Nursing, MD, Pediatrics, Child, Cancer

NEW YORK, Oct. 30, 2023 /PRNewswire/ -- The Department of Pediatrics at NYU Langone Health has received $9.8 million from NYU Langone trustee Trudy Elbaum Gottesman and Robert W. Gottesman, founding donors of Sala Institute for Child and Family Centered Care, which has profoundly influenced excellence in clinical care across Hassenfeld Children's Hospital at NYU Langone since 2013.

Key Points: 
  • NEW YORK, Oct. 30, 2023 /PRNewswire/ -- The Department of Pediatrics at NYU Langone Health has received $9.8 million from NYU Langone trustee Trudy Elbaum Gottesman and Robert W. Gottesman, founding donors of Sala Institute for Child and Family Centered Care , which has profoundly influenced excellence in clinical care across Hassenfeld Children's Hospital at NYU Langone since 2013.
  • "We are proud to support innovations in pediatric research and career growth of physician–scientists," said Trudy Elbaum Gottesman.
  • "Providing exceptional care means understanding the unique needs of the patients we see at NYU Langone Health—and there is often no patient more vulnerable, or more resilient, than a child," said Robert I. Grossman, MD , dean of NYU Grossman School of Medicine and CEO of NYU Langone Health.
  • "This fund will help us continue to provide top-notch training to our pediatric fellows, ensuring more pediatric physicians have deep experience in child- and family-centered care."